Scientists have identified a rare, inherited eye condition that gradually erodes night vision and peripheral sight, a discovery that contrasts with earlier research on the same gene.
While a previously known disorder associated with the EFEMP1 gene primarily damages central vision, the newly described condition begins in the outer retina, sparing central acuity for much of a patient’s life.
The investigation, published in JAMA Ophthalmology, traces back to 1998 when doctors documented an unusual pattern of vision loss in a United States family. As genetic evidence accumulated, researchers connected those findings to families in Europe with similar symptoms.
An international team — including scientists from the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine, the University of Edinburgh, the University of Basel, Charles University, and the University of Bonn — examined three unrelated families carrying the EFEMP1 variant p.Arg140Trp and compared them with a family carrying the known p.Arg345Trp variant.
The p.Arg345Trp variant causes Doyne honeycomb retinal dystrophy, also known as malattia leventinese, an autosomal dominant disorder characterized by early-onset, large central retinal drusen. In contrast, the p.Arg140Trp variant drives a disease the researchers are calling EFEMP1-associated late-onset retinal degeneration (L-ORD).
It causes an abnormally thick accumulation of material between cells in the eye and begins in the peripheral retina, the region responsible for side vision and low-light detection.
“The different disease expression in this family was thought to be similar to a condition caused by C1QTNF5 gene variants. However, none of the variants associated with that disease were found,” said Artur V. Cideciyan, PhD, an ophthalmology researcher and co-director of the Center for Hereditary Retinal Degenerations.
“Our collaborators then discovered a new variant in the EFEMP1 gene that normally causes a different disease where the macula, which is tied to central vision, is affected first.”
People with the new condition may see normally for decades before noticing that their side vision is narrowing or that seeing in dim surroundings has become more difficult, particularly around dusk or at night when the eyes rely on rod photoreceptors. The disease is challenging to diagnose because these cells may initially show no visible structural damage.
However, the researchers identified a functional biomarker. Those who are affected experience a markedly prolonged recovery of rod cells when their eyes shift from bright surroundings into darkness. This abnormal response can be detected even when the retina still appears structurally normal.
“We can detect a major abnormality in the way rod photoreceptors recover in darkness with retinas that still look structurally intact,” Cideciyan said. “This gives us a functional marker of disease at a stage when photoreceptor cells have not yet been lost.”
The study, a multi-institutional case series conducted at clinics in Philadelphia, Basel, and Prague from October 1998 to May 2026, included five at-risk relatives aged 50 to 58 in the first family. Four heterozygous carriers showed delayed rod-mediated dark adaptation kinetics despite best-corrected visual acuity of 20/20.
The researchers do not yet know how widespread the p.Arg140Trp variant is. They suspect it may be relatively rare, but larger studies are needed to establish its prevalence.
“Aging is a risk factor for many medical conditions, including retinal diseases such as age-related macular degeneration, the most common retinal condition of aging,” said Tomas S. Aleman, MD, a professor of ophthalmology who also serves as co-director of the Center for Hereditary Retinal Degenerations. “Lessons learned from these infrequent, late-onset genetic eye diseases offer glimpses at possible mechanisms of disease for much more frequent retinal problems.”